Bleomycin

Therapeutic

For palliative treatment in the management malignant neoplasm (trachea, bronchus, lung), squamous cell carcinoma, and lymphomas.

Structural features

SMILES

CC1=C(N=C(N=C1N)[C@H](CC(=O)N)NC[C@@H](C(=O)N)N)C(=O)N[C@@H]([C@H](C2=CN=CN2)O[C@H]3[C@H]([C@H]([C@@H]([C@@H](O3)CO)O)O)O[C@@H]4[C@H]([C@H]([C@@H]([C@H](O4)CO)O)OC(=O)N)O)C(=O)N[C@H](C)[C@H]([C@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCCC5=NC(=CS5)C6=NC(=CS6)C(=O)NCCC[S+](C)C)O

Sequence

-

Molar mass

1415.55 g/mol

Constitutional members:

N.A.

Natural amino acids

N.A.

D-Amino acids

N.A.

N-terminus

N.A.

C-terminus

N.A.

Cyclic

no

Members/cycle

N.A.

Bond to form cycle

N.A.

Lipidation

no

Glycosylation

yes - 2 sugars

Route of administration

IM, IV, SC, IP, IA, IC

Terminal half-life

115 min

Protein binding

0.01

Absorption and Bioavailability

0.45

References